A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

ABSTRACT:

Background

Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is commercially available and increasingly adopted in clinical practice despite a paucity of prospective data to support its use.

Methods

Patients with advanced lung cancers who had no known oncogenic driver or developed resistance to current targeted therapy (n = 210) underwent plasma NGS, targeting 21 genes. A subset of patients had concurrent tissue NGS testing using a 468-gene panel (n = 106). Oncogenic driver detection, test turnaround time (TAT), concordance, and treatment response guided by plasma NGS were measured. All statistical tests were two-sided.

Results

Somatic mutations were detected in 64.3% (135/210) of patients. ctDNA detection was lower in patients wh

SUBMITTER: Sabari JK 

PROVIDER: S-EPMC6579739 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature